Immunochina secures $20.5m Series C round

Other participants include Shougang Fund, Qingzhe Capital, China Resources Innovative Equity Investment Fund, and healthcare specialist Sherpa Venture Capital. 

According to a statement, the round was recently increased to incorporate additional investors on the back of new positive clinical testing results. Previous backers include Legend Capital and Tsinghua University's DNA Fund.

Founded in 2015, Immunochina focuses on cancer treatment technologies and is touted as one of only a few cell therapy companies in China that has end-to-end research and development capabilities. It will use the fresh capital to advance trials on its lead product, which is targeting non-Hodgkin's lymphoma along with a form of leukemia common in children.

Last month, Immunochina partnered with a China-based affiliate of French biopharmaceuticals supplier Sartorius Stedim Biotech (SSB), gaining access to the company's bioprocess technology platform for product development, scaling, and manufacturing. 

"Cell and gene therapy are very important new modalities offering new hope to patients and Immunochina is pioneering fast and promising progress in this field in China," Floris De Smet, head of technical specialists and process support at SSB China, said in a release. "The cooperation between the two companies will open a new chapter in precision treatment of hematological tumors."

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Save this article  
• Send to  

• Topics
• Greater China
• Healthcare
• Early-stage
• China
• Pharmaceuticals
• Venture